The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
about
Auditory dysfunction in schizophrenia: integrating clinical and basic features.Classics in Chemical Neuroscience: Aripiprazole.mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.The importance of the excitatory amino acid transporter 3 (EAAT3)Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.Substantial DNA methylation differences between two major neuronal subtypes in human brain.Using human brain imaging studies as a guide toward animal models of schizophrenia.Investigational dopamine antagonists for the treatment of schizophrenia.Overview of Glutamatergic Dysregulation in Central Pathologies.Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.Molecular evidence of synaptic pathology in the CA1 region in schizophrenia.Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study.Mouse pups lacking collapsin response mediator protein 4 manifest impaired olfactory function and hyperactivity in the olfactory bulb.Genetic tests in major psychiatric disorders-integrating molecular medicine with clinical psychiatry-why is it so difficult?Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse"Targeting astrocytes in CNS injury and disease: A translational research approach".The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia.Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.Alteration in plasma and striatal levels of d-serine after d-serine administration with or without nicergoline: An in vivo microdialysis study.The involvement of DARPP-32 in the pathophysiology of schizophrenia.Cross Talk: The Microbiota and Neurodevelopmental Disorders.The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders.Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.DNA Methylation Changes in Intron 1 of Triggering Receptor Expressed on Myeloid Cell 2 in Japanese Schizophrenia Subjects.Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker.Post-zygotic genomic changes in glutamate and dopamine pathway genes may explain discordance of monozygotic twins for schizophrenia.Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients.Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits.S-Ketamine-Induced NMDA Receptor Blockade during Natural Speech Production and Its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia.A cell culture model for investigation of synapse influenceability: epigenetics, expression and function of gene targets important for synapse formation and preservation in SH-SY5Y neuroblastoma cells differentiated by retinoic acid.Genetic insights into the neurodevelopmental origins of schizophrenia.Elevated TREM2 mRNA expression in leukocytes in schizophrenia but not major depressive disorder.The methylazoxymethanol acetate rat model: molecular and epigenetic effect in the developing prefrontal cortex: An Editorial Highlight for 'Epigenetic mechanisms underlying NMDA receptor hypofunction in the prefrontal cortex of juvenile animals in tA systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.Altered Gradients of Glutamate and Gamma-Aminobutyric Acid Transcripts in the Cortical Visuospatial Working Memory Network in Schizophrenia.Elevated mRNA expression of CASPR3 in patients with schizophrenia.SchizophreniaIdentification of expression quantitative trait loci associated with schizophrenia and affective disorders in normal brain tissue
P2860
Q26796401-0F8DAC29-23E7-4823-A044-C40DEE3394CDQ33866125-76CA7099-9665-477B-B5A2-8169061A7110Q34513221-7967DC78-CE55-4011-BA74-7FCB82230E13Q34528594-243ED22A-C45C-47A1-B5BC-3144691C4C2AQ35591134-36FE568C-2F94-4FB2-B45D-943744A7A0BBQ35854307-C914F608-F50D-413C-8B18-4C82D28F0C04Q36332602-ABA63357-AD9A-4C6E-8BE3-D1BE31ED24CAQ36356306-E06D0480-499B-4A6F-BAEF-354572E681F1Q36409596-734FB1FD-C01A-4C11-B91A-94AF29959717Q36986134-9A431DC5-45EE-4B7C-B6C4-7BF3922DEB33Q37094982-2ED71A3D-B052-4DFB-999B-ABC130B7E8F7Q37486473-92F03559-11D6-4DA8-98F9-A8F55DCE7B9DQ38297966-34EF68A9-E65D-465F-BCFD-0CC8930290E7Q38671562-58BE35A1-F377-42B5-ABE0-E0C202556EF9Q38729846-B2FCC9CA-1ABE-4611-87E5-6924CA8CD43EQ38793073-BA7A53A1-096E-48E2-9C99-857DFB33D1B1Q38863895-4CE3C311-8B8E-4034-A04D-44A87C83AAD9Q38970065-F2A84C5C-6BB1-4599-9EA1-3AD345FD8486Q39036691-663FF0C0-8D31-4550-A0C9-8EE078CAF9C7Q41472750-6E8E893A-48F8-4D7C-9295-195CF071E447Q41593397-0DD4F64B-9092-4F40-B17B-D7770EF376D8Q41665354-685511BB-FDDA-4D0B-8D87-E9DE8F5D2ED6Q41693925-678CDCBF-2BDF-4B57-91D3-34CC110B1579Q42034477-3C338B50-7DE1-46C7-B04D-00B88F7570B2Q42251222-ADDF5F96-6D11-4E19-A0B5-2DB97C4C0A9DQ46516683-B447C6A6-25AF-41D7-B5BB-7CDBC41524A5Q47135953-0F39FE0E-0627-470A-9490-F23A03CEB6A6Q47316985-803DC7A9-E4F8-4A6C-9833-5A0FEA81EE17Q47318364-90942BE7-17EA-460E-B625-F4A9B1FD6968Q47580337-72231C0A-7CA1-4834-99F4-1AD41338DEA4Q47664140-D926A329-B99D-49D2-9986-889660419420Q47703847-3B2C38DF-D22D-490F-B5DA-F660FF8D9333Q47717598-0D4301F0-2E14-428A-9C40-B738DFC0FCD6Q48056770-777F9023-5D63-4BF9-BBA4-F88B9FD234BEQ48126673-75DDED93-9546-49CA-80BD-C607C06E800CQ48137280-F8D738C0-D4B5-41A5-B2E0-89E4AC0C72BAQ50540728-545526F1-4587-4415-8870-742A5D89C777Q50724485-7E5D2BB0-CFC6-4D18-A1EC-298835B9F9DCQ56959104-AC2A4F36-4984-4D72-8992-62DC18D6513EQ57677495-C62F1E26-C5C7-4211-953E-1570821C5861
P2860
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@ast
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@en
type
label
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@ast
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@en
prefLabel
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@ast
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@en
P2093
P2860
P356
P1476
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.
@en
P2093
Daniel E Elswick
Matthew L MacDonald
Robert A Sweet
P2860
P356
10.1111/NYAS.12547
P407
P577
2014-10-14T00:00:00Z